Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya

Breast

Volumn 23, Issue 5, 2014, Pages 591-596

  Sayed, Shahin ^a   Moloo, Zahir ^a   Wasike, Ronald ^a   Bird, Peter ^b   Oigara, Raymond ^c   Govender, Dhirendra ^d   Kibera, Joshua ^a   Carrara, Henri ^d   Saleh, Mansoor ^e  

^a AGA KHAN UNIVERSITY   (Kenya)

^b Kijabe Mission Hospital   (Kenya)

^c Department of Surgery   (Kenya)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Breast cancer; Hormone receptors; Sub Saharan Africa

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AFRICA SOUTH OF THE SAHARA; AGED; ANALYTIC METHOD; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KENYA; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PREVALENCE; STANDARDIZATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; UNIVERSITY HOSPITAL; ADENOCARCINOMA, MUCINOUS; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; KENYA; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREVALENCE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84920808771     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.06.006     Document Type: Article

References (22)

1. GLOBOCON IARC 2013 2012, http://www-dep.iarc.fr/.
2. Gakwaya A., Galukande M., Luwaga A., Jombwe J., Fualal J., Baguna P., et al. Breast cancer guidelines for Uganda (2nd edition 2008). Afr Health Sci 2008, 8(2):126-132.
3. Ihekwaba F.N. Breast cancer in Nigerian women. Br J Surg 1992, 79:771-775.
4. Bowa K., Wood C., Chao A., Chintu C., Mudenda V., Chikwenya M. Areview of the epidemiology of cancers at the University Teaching Hospital, Lusaka, Zambia. Trop Doct 2009, 39(1):5-7.
5. Sally N.A., Temidayo O.O., Adebamowo C.A. Emerging breast cancer epidemic: evidence form Africa. Breast Cancer Res 2010, 12(Suppl.4):S8.
6. Valarie A.M., Maureen J., Eunice V.B. Breast cancer receptor status diagnosis in over 1200 consecutive public hospital patients in Soweto South Africa: a cases series. Breast Cancer Res 2013, 15. R84:1-13.
7. Ohene Y.M., Adjei E. Breast cancer in Kumasi, Ghana. Ghana Med J 2012, 46(1):8-13.
8. Stark A., Celina G.K., Iman M., Baffour A., Anthony N.A., Valarie T., et al. African ancestry and higher prevalence of triple negative breast cancer. Cancer 2010, 116(21):4926-4932.
9. Adebamowo C.A., Famooto A., Ogundian T.O., Aniagwu T., Nkwodiammah C., Akang E.E. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 2008, 110(1):183-188.
10. Nyagol J., Nyong'o A., Byakika B., Muchiri L., Cocco M., Spina D., et al. Routine assessment of hormonal receptors and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. Anal Quant Cytol Histol 2006 Apr, 28(2):97-103.
11. Gakinya S.M., Sayed S., Chauhan R. Breast cancer molecular subtypes and their clinicopathological characteristics amongst patients at the Aga Khan University Hospital (Nairobi). Ann Afr Surg 2010, 5:19-24.
12. Bird P.A., Hill G.A., Housami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?. Ann Surg Oncol 2008, 15(7):1983-1988.
13. Gukas I.D., Jennings B.A., Leinster S.J., Mandong B.M., Igun G.O., Girling A.C., et al. Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr J Med 2005, 24(3):209-213.
14. Indrojit R., Othieno E. Breast cancer in Uganda microscopic study and receptor profile of 45 cases. Arch Pathol Lab Med 2011 Feb, 135(2):194-199.
15. Allred D.C., Harvey J.M., Bernado M., Clark B. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.
16. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. JClin Oncol 2013 Nov 1, 31(31):3997-4013.
17. Hammond M.E.H., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010, 134:907-922.
18. Meijer S.L., Wesseling J., Smit V.T., Nederlof P.M., Hooijer G.K.J., Ruijter H., et al. HER2 gene amplification in patients with breast cancer with equivocal IHC results. JClin Pathol 2011, 64(12):1069-1072.
19. Mateya T., Sayed S., Mukono S., Moloo Z., Yasmin R. Basal-like breast cancer in East Africa. Breast J 2011, 17:438-440.
20. Traore A., Traore C., Dembele B.T., Kante L., Diakite I., Maiga A., et al. Cancer du sein dans deux centres hospitaliers de Bamako (Mali): aspects diagnostiques et thérapeutiques. JAfr Cancer 2010, 2:88-91.
21. Anderson W.F., Katki H.A., Rosenberg P.S. Incidence of breast cancer in the United States: current and future trends. JNatl Cancer Inst 2011, 103:1397-1402.
22. Parise C.A., Bauer K.R., Brown M.M., Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009, 15(6):593-602.